Therapeutic modulation of the CD47-SIRPα axis in the pediatric tumor microenvironment: working up an appetite
Authors:
Open Access
- 1 January 2020
- journal article
- review article
- Published by OAE Publishing Inc. in Cancer Drug Resistance
- Vol. 3 (3) , 550-562
Abstract
Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc. Both clinical and experimental aspects of drug resistance in cancer are included.Keywords
This publication has 79 references indexed in Scilit:
- Engagement of SIRPα Inhibits Growth and Induces Programmed Cell Death in Acute Myeloid Leukemia CellsPLOS ONE, 2013
- Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenograftsJournal of Experimental Medicine, 2012
- Susceptibility of rhabdomyosarcoma cells to macrophage-mediated cytotoxicityOncoImmunology, 2012
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsProceedings of the National Academy of Sciences, 2012
- CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destructionProceedings of the National Academy of Sciences, 2011
- Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic LeukemiaCancer Research, 2011
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin LymphomaCell, 2010
- Macrophages as mediators of tumor immunosurveillanceTrends in Immunology, 2010
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid PhagocytosisCell, 2009
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009